Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) – Investment analysts at Jefferies Financial Group dropped their FY2020 earnings estimates for Alexion Pharmaceuticals in a report released on Wednesday, October 16th. Jefferies Financial Group analyst E. Yang now forecasts that the biopharmaceutical company will post earnings of $8.74 per share for the year, down from their prior forecast of $8.90.
Other research analysts have also issued research reports about the company. Credit Suisse Group cut their price objective on Alexion Pharmaceuticals from $154.00 to $146.00 and set an “outperform” rating for the company in a research report on Friday, September 6th. Royal Bank of Canada restated a “buy” rating on shares of Alexion Pharmaceuticals in a research report on Wednesday, September 18th. BMO Capital Markets began coverage on Alexion Pharmaceuticals in a research report on Thursday, September 12th. They set an “outperform” rating and a $149.00 price objective for the company. William Blair began coverage on Alexion Pharmaceuticals in a research report on Thursday, September 26th. They set an “outperform” rating and a $146.00 price objective for the company. Finally, Stifel Nicolaus restated a “hold” rating on shares of Alexion Pharmaceuticals in a research report on Friday, August 30th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and fifteen have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $159.76.
Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings data on Wednesday, July 24th. The biopharmaceutical company reported $2.64 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.13 by $0.51. The firm had revenue of $1.20 billion during the quarter, compared to analyst estimates of $1.18 billion. Alexion Pharmaceuticals had a return on equity of 20.23% and a net margin of 29.64%. The business’s quarterly revenue was up 15.1% compared to the same quarter last year. During the same quarter last year, the business posted $2.07 earnings per share.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in ALXN. United Bank bought a new stake in Alexion Pharmaceuticals in the first quarter worth about $929,000. Amundi Pioneer Asset Management Inc. lifted its stake in Alexion Pharmaceuticals by 15.8% in the first quarter. Amundi Pioneer Asset Management Inc. now owns 811,367 shares of the biopharmaceutical company’s stock worth $109,681,000 after purchasing an additional 110,593 shares during the last quarter. Nordea Investment Management AB lifted its stake in Alexion Pharmaceuticals by 199.3% in the first quarter. Nordea Investment Management AB now owns 36,102 shares of the biopharmaceutical company’s stock worth $4,881,000 after purchasing an additional 24,041 shares during the last quarter. Boltwood Capital Management bought a new stake in Alexion Pharmaceuticals in the second quarter worth about $921,000. Finally, Private Trust Co. NA lifted its stake in Alexion Pharmaceuticals by 3.6% in the second quarter. Private Trust Co. NA now owns 16,054 shares of the biopharmaceutical company’s stock worth $2,102,000 after purchasing an additional 560 shares during the last quarter. Institutional investors own 93.26% of the company’s stock.
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.